91¹ú²ú¾«Æ·

Academic Centers, Hospitals, and Community Practices

• (COVID-19 Critical Care Clinical Guidelines)
• (patient screening and testing tools, PPE donning and doffing videos, telehealth FAQs)
• (Screening and testing algorithms, policies and procedures)

Archived Frequently Asked Clinical Questions

Treatments and Prevention

• General Principles of COVID-19 Vaccines for Immunocompromised Patients (Version 6.1; last April 14, 2022)
• COVID-19 Therapies: Monoclonal Antibodies, Convalescent Plasma and Medications (Version 9.2; last updated April 7, 2022)
• Prevention of COVID-19 in Immunocompromised Patients With Hematologic Conditions (Version 2; last updated April 6, 2023)

Malignant Topics

• COVID-19 and Aggressive Non-Hodgkin Lymphoma (Version 6.0; last updated April 1, 2022)
• COVID-19 and Acute Lymphoblastic Leukemia - Adult (Version 2.1; last updated January 22, 2021)
• COVID-19 and Acute Lymphoblastic Leukemia - Pediatric (Version 3.0; last updated January 29, 2021)
• COVID-19 and Acute Myeloid Leukemia (Version 1.5; last reviewed January 19, 2022)
• COVID-19 and Chronic Lymphocytic Leukemia (Version 4.1; last updated February 2, 2021)
• COVID-19 and Chronic Myeloid Leukemia (Version 3.0; last updated September 28, 2021)
• COVID-19 and Hematopoietic Cell Transplantation (Version 2.0; last updated April 1, 2022)
• COVID-19 and Hodgkin Lymphoma (Version 6.0; last updated April 1, 2022)
• COVID-19 and Indolent Lymphomas (Version 6.0; last updated April 1, 2022)
• COVID-19 and Myelodysplastic Syndromes (Version 4.2; last updated May 17, 2021)
• COVID-19 and Myeloproliferative Neoplasms (Version 6.0; last updated September 3, 2021)
• COVID-19 and Multiple Myeloma (Version 2.1; last updated January 22, 2021)

Non-malignant Topics

• COVID-19 and Aplastic Anemia (Version 3.0; last updated May 6, 2021)
• COVID-19 and Immune Thrombocytopenic Purpura (Version 6.1; last updated April 21, 2021)
• COVID-19 and Sickle Cell Disease (Version 6.1; last updated May 28, 2021)
• COVID-19 and Thalassemia (Version 2.1; last updated January 19, 2022)
• COVID-19 and Thrombotic Thrombocytopenic Purpura (Version 3.3; last updated April 4, 2022)
• COVID-19 and VTE/Anticoagulation (Version 14.0; last updated February 2, 2022)

Clinical Laboratory Topics

• COVID-19 and aPL Antibodies (Version 1.1; last updated February 2, 2022)
• COVID-19 and D-dimer (Version 1.0; last updated April 20, 2020)
• COVID-19 and Viscoelastic Hemostasis Assays (Version 2.0; last updated February 25, 2021)

Clinical FAQ Resources from Other Societies

COVID-19 Treatments

Guidance About COVID-19 Treatment

• Assessment of Evidence for COVID-19 related treatments
• 24-hour access to CDC clinicians to answer COVID-19 questions.

Clinical Trials and Studies

COVID-19 Registries for Hematologic Conditions

• 
  The 91¹ú²ú¾«Æ· Collaborative’s (ASH RC) Data Hub is capturing data on people who test positive for COVID-19 and have been or are currently being treated for a hematologic condition. As data are received, near real-time observational data summaries are reported for clinicians on the front line of the COVID-19 pandemic. Clinicians and other health care providers worldwide are invited to enter de-identified data on all confirmed COVID-19 cases for hematology patients, regardless of recovery or active treatment status. Online data entry takes approximately 5 minutes to complete.
• 
  This registry is designed to capture pediatric and adult COVID-19 cases that are occurring across the world in patients living with sickle cell disease.
• 
  A consortium of over 100 cancer centers and other organizations who have come together to collect data about cancer patients who have been infected with COVID-19.

Restarting Routine Clinical Practice

Additional Resources

91¹ú²ú¾«Æ·

• ASH Policy Resources
• ASH Summary of American Rescue Plan Act of 2021
• ASH Summary of the Coronavirus Aid, Relief and Economic Security (CARES) Act
• Latest COVID-19 Resources from ASH Publications
  • Blood:
  • Blood Advances:
  • ASH Clinical News: 
  • The Hematologist: COVID-19 Articles and Podcasts 

Archived Webinars

COVID-19: General Resources

 

Subspecialty Societies

 

EHA (European Hematology Association)

Journals

New England Journal of Medicine

The Lancet

Journal of Thrombosis and Haemostasis

•  

British Journal of Haematology

Additional Resources

•  (manual for front-line providers)

Resources for Researchers

91¹ú²ú¾«Æ·

• ASH COVID-19 Research Agenda for Hematology
• Summary of NIH Guidance on Grants, Operations During COVID-19 Response

• CDC and NIH have developed the COVID-19 Seroprevalence Studies Hub to provide an interactive dashboard to compare COVID19 serology studies across the country. 
• – expires 9/1/2021

Other Resources

• This hub tracks up-to-date scientific information about COVID-19. Articles are updated daily and are categorized by different research topics and geographic locations.
•  
  Dr. Kellie Machlus from Harvard Medical School and Brigham and Women’s Hospital has organized this seminar series to continue scientific education during this time of travel restrictions and meeting cancellations.
•  
  Drs. Kornelia Polyak and David Weinstock from Dana-Farber/Harvard Cancer Center have organized this seminar series (12:00 pm Eastern every Tuesday and Thursday) to facilitate scientific exchanges during the COVID-19 restrictions.

Resources for Trainees

Frequently Asked Questions

• COVID-19 and Trainees: General Information (Version 1.1; last updated October 6, 2020)
• COVID-19 and Fellows (Version 1.1; last updated October 6, 2020)
• COVID-19 and Postdoctorate Students (Version 1.1; last updated October 6, 2020)
• COVID-19 and Residents (Version 1.1; last updated October 6, 2020)